clorazepate dipotassium has been researched along with buspirone in 9 studies
| Studies (clorazepate dipotassium) | Trials (clorazepate dipotassium) | Recent Studies (post-2010) (clorazepate dipotassium) | Studies (buspirone) | Trials (buspirone) | Recent Studies (post-2010) (buspirone) |
|---|---|---|---|---|---|
| 325 | 90 | 11 | 2,096 | 351 | 382 |
| Protein | Taxonomy | clorazepate dipotassium (IC50) | buspirone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 1.75 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.024 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.323 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 2.125 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| D | Rattus norvegicus (Norway rat) | 0.12 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0266 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 4 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.077 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.286 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.016 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 2.125 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.044 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.75 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.2055 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.9811 | |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.025 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.7 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.2666 | |
| Lysosomal alpha-glucosidase | Bos taurus (cattle) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowden, CL; Cohn, JB; Fisher, JG; Rodos, JJ | 1 |
| Alderdice, MT; Marunycz, JD; Napoliello, MJ; Newton, RE | 1 |
| Case, WG; Chung, H; Csanalosi, I; Rickels, K; Schweizer, E | 1 |
| Rickels, K; Schweizer, E | 1 |
| Alms, DR; Benes, CO; Casten, GP; Marunycz, JD; Newton, RE | 1 |
| Balster, RL; Woolverton, WL | 1 |
| Gershon, S | 1 |
| Finnerty, R; Goldberg, HL | 1 |
| Sussman, N | 1 |
2 review(s) available for clorazepate dipotassium and buspirone
| Article | Year |
|---|---|
Review of the side-effect profile of buspirone.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Diazepam; Dizziness; Double-Blind Method; Drug Evaluation; Fatigue; Headache; Humans; Lorazepam; Pyrimidines | 1986 |
Treating anxiety while minimizing abuse and dependence.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clorazepate Dipotassium; Humans; Substance Withdrawal Syndrome; Substance-Related Disorders | 1993 |
7 trial(s) available for clorazepate dipotassium and buspirone
| Article | Year |
|---|---|
Double-blind comparison of buspirone and clorazepate in anxious outpatients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Depression; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrimidines; Random Allocation | 1986 |
Review of the side-effect profile of buspirone.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Diazepam; Dizziness; Double-Blind Method; Drug Evaluation; Fatigue; Headache; Humans; Lorazepam; Pyrimidines | 1986 |
Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Outcome and Process Assessment, Health Care; Panic; Patient Compliance; Patient Dropouts; Personality Inventory; Prospective Studies; Psychiatric Status Rating Scales; Substance Withdrawal Syndrome | 1988 |
Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate.
Topics: Adult; Anti-Anxiety Agents; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Double-Blind Method; Fear; Female; Humans; Male; Panic; Pilot Projects; Prospective Studies; Random Allocation | 1988 |
The side effect profile of buspirone in comparison to active controls and placebo.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Depression; Diazepam; Double-Blind Method; Headache; Humans; Nausea; Placebos; Pyrimidines; Sleep Stages | 1982 |
Drug interactions in controlled clinical trials.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Diazepam; Drug Interactions; Drug Therapy, Combination; Humans; Placebos; Pyrimidines; Sleep Stages | 1982 |
Comparison of buspirone in two separate studies.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Buspirone; Clinical Trials as Topic; Clorazepate Dipotassium; Depression; Diazepam; Double-Blind Method; Female; Humans; Male; Personality Inventory; Psychiatric Status Rating Scales; Pyrimidines | 1982 |
1 other study(ies) available for clorazepate dipotassium and buspirone
| Article | Year |
|---|---|
Intravenous buspirone self-administration in rhesus monkeys.
Topics: Animals; Anti-Anxiety Agents; Buspirone; Chlordiazepoxide; Clorazepate Dipotassium; Cocaine; Conditioning, Operant; Injections, Intravenous; Macaca mulatta; Pyrimidines; Reinforcement, Psychology; Self Administration; Sodium Chloride | 1982 |